Io Biotech Stock Price To Earning
| IOBT Stock | USD 0.71 0.03 4.41% |
IO Biotech fundamentals help investors to digest information that contributes to IO Biotech's financial success or failures. It also enables traders to predict the movement of IOBT Stock. The fundamental analysis module provides a way to measure IO Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IO Biotech stock.
IOBT | Price To Earning |
IO Biotech Company Price To Earning Analysis
IO Biotech's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
IOBT Price To Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for IO Biotech is extremely important. It helps to project a fair market value of IOBT Stock properly, considering its historical fundamentals such as Price To Earning. Since IO Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IO Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IO Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
IOBT Retained Earnings
Retained Earnings |
|
Based on the latest financial disclosure, IO Biotech has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.
IOBT Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IO Biotech's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IO Biotech could also be used in its relative valuation, which is a method of valuing IO Biotech by comparing valuation metrics of similar companies.IO Biotech is currently under evaluation in price to earning category among its peers.
IOBT Fundamentals
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | (33.24 M) | ||||
| Shares Outstanding | 65.88 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 76.79 % | ||||
| Number Of Shares Shorted | 200.92 K | ||||
| Price To Book | 0.62 X | ||||
| EBITDA | (91.23 M) | ||||
| Net Income | (86.08 M) | ||||
| Cash And Equivalents | 170.12 M | ||||
| Cash Per Share | 5.90 X | ||||
| Total Debt | 2.49 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 20.94 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (71.74 M) | ||||
| Short Ratio | 1.89 X | ||||
| Earnings Per Share | (1.29) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 74 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 44.93 M | ||||
| Total Asset | 150.72 M | ||||
| Retained Earnings | (263.82 M) | ||||
| Working Capital | 131.54 M | ||||
| Net Asset | 150.72 M |
About IO Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IO Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IO Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IO Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.